Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HINDthis companyVyome Holdings, Inc.	$1.57	-0.72×	3.04×	23.26×	-0.24×	5.9%	64.7%	-859.2%	-3209.7%	-420.2%	-72.4%	-50.4%	0.01×	0.48×	-18.73×	1.99×	0.0%	3	-12.95	3	B-
ARMPArmata Pharmaceuticals, Inc.	$3.36	-1.31×	-1.04×	46.41×	-3.26×	-475.8%	68.8%	-636.7%	-3544.0%	79.5%	-43.1%	-11.6%	-1.32×	-1.79×	-1.88×	1.19×	0.0%	2	-17.44	2	C
CCCCC4 Therapeutics, Inc.	$3.19	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
CDXSCodexis, Inc.	$1.13	-3.26×	2.81×	2.02×	-4.86×	-459.7%	86.7%	-54.5%	-62.5%	-87.0%	-30.6%	-16.8%	1.45×	-0.66×	-7.96×	3.82×	0.0%	3	-6.21	1	D+
IMDXInsight Molecular Diagnostics Inc.	$2.67	-4.55×	-7.26×	56.37×	-4.6×	-189.3%	4.7%	-754.1%	-1238.5%	159.6%	-197.4%	-11.1%	-0.11×	0.17×	-280.53×	1.27×	0.0%	1	-23.74	2	C
NVCTNuvectis Pharma, Inc.	$20.63	-5.72×	8.94×	0×	-5.03×	-93.9%	0.0%	0.0%	0.0%	-143.6%	-149.8%	-9.7%	0×	1.2×	0×	2.38×	0.0%	1	17.43	1	D+
Peer median	—	-3.26×	0.62×	4.4×	-4.6×	-189.3%	68.8%	-290.7%	-292.1%	-40.9%	-43.1%	-11.6%	0×	0.14×	-1.88×	2.38×	0.0%	2	-6.21	2	—